Ionis Pharmaceuticals, Inc.

As of June 30, 2026, Ionis Pharmaceuticals, Inc. carries a market capitalization of 194.16B, placing it among publicly traded companies globally. Its enterprise value stands at 186.45B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Ionis Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Ionis Pharmaceuticals, Inc. has 165.90M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 12.49, and the price-to-book ratio stands at 25.27.

These figures are as of June 30, 2026. The EV/Sales ratio of 12.21 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 186.45B versus a market cap of 194.16B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Ionis Pharmaceuticals, Inc. maintains a current ratio of 7.89, meaning it holds 7.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 366.93, indicating elevated leverage, while an interest coverage ratio of -6.88 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Ionis Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -105.50, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -18.90, reflecting losses generated across the asset base. The company generates approximately 11.58M in revenue per employee across its workforce of 1,318.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.54 indicates how many times Ionis Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Ionis Pharmaceuticals, Inc. recorded 55.44M in income tax expense. The company reported a pretax loss of -9.82B and -9.87B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on September 10, 2026, Ionis Pharmaceuticals, Inc.'s stock has declined approximately 18.64% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Ionis Pharmaceuticals, Inc. generated 15.27B in revenue and converted that into -9.87B in net income, yielding earnings per share of -60.57. EBITDA reached -9.91B, while operating income came in at -10.39B.

As of June 30, 2026, Ionis Pharmaceuticals, Inc. holds 35.90B in cash and equivalents against 28.19B in total debt, resulting in a net debt position of 17.49B. Total book value stands at 7.68B, with working capital of 38.01B providing operational flexibility.

Ionis Pharmaceuticals, Inc. produced -8.67B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.24B in capital expenditures, free cash flow totaled -9.92B - equivalent to -60.82 per share.

Over the twelve months ended June 30, 2026, Ionis Pharmaceuticals, Inc. posted a gross margin of 98.17, reflecting its pricing power and cost economics. The operating margin of -68.01 and net profit margin of -64.66 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -5.20: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.86, meaning Ionis Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Ionis Pharmaceuticals, Inc. has an Altman Z-Score of 1.79, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.